Subcutaneous Tissue

  • XW013 - Percutaneous
    • XW0131
      • XW01318 - Introduction Subcutaneous Tissue to New Technology Group 8 with Daratumumab and Hyaluronidase-fihj, Percutaneous Approach
    • XW0132
      • XW01329 - Introduction Subcutaneous Tissue to New Technology Group 9 with Talquetamab Antineoplastic, Percutaneous Approach
    • XW0134
      • XW01348 - Introduction Subcutaneous Tissue to New Technology Group 8 with Teclistamab Antineoplastic, Percutaneous Approach
    • XW0136
      • XW0136A - Introduction Subcutaneous Tissue to New Technology Group 10 with Dasiglucagon, Percutaneous Approach
    • XW0139
      • XW01397 - Introduction Subcutaneous Tissue to New Technology Group 7 with Satralizumab-mwge, Percutaneous Approach
    • XW013F
      • XW013F5 - Introduction Subcutaneous Tissue to New Technology Group 5 with Other New Technology Therapeutic Substance, Percutaneous Approach
    • XW013G
      • XW013G6 - Introduction Subcutaneous Tissue to New Technology Group 6 with REGN-COV2 Monoclonal Antibody, Percutaneous Approach
    • XW013H
      • XW013H6 - Introduction Subcutaneous Tissue to New Technology Group 6 with Other New Technology Monoclonal Antibody, Percutaneous Approach
    • XW013K
      • XW013K6 - Introduction Subcutaneous Tissue to New Technology Group 6 with Leronlimab Monoclonal Antibody, Percutaneous Approach
    • XW013L
      • XW013L9 - Introduction Subcutaneous Tissue to New Technology Group 9 with Elranatamab Antineoplastic, Percutaneous Approach
    • XW013S
      • XW013S6 - Introduction Subcutaneous Tissue to New Technology Group 6 with COVID-19 Vaccine Dose 1, Percutaneous Approach
      • XW013S9 - Introduction Subcutaneous Tissue to New Technology Group 9 with Epcoritamab Monoclonal Antibody, Percutaneous Approach
    • XW013T
      • XW013T6 - Introduction Subcutaneous Tissue to New Technology Group 6 with COVID-19 Vaccine Dose 2, Percutaneous Approach
    • XW013U
      • XW013U6 - Introduction Subcutaneous Tissue to New Technology Group 6 with COVID-19 Vaccine, Percutaneous Approach
    • XW013V
      • XW013V7 - Introduction Subcutaneous Tissue to New Technology Group 7 with COVID-19 Vaccine Dose 3, Percutaneous Approach
    • XW013W
      • XW013W5 - Introduction Subcutaneous Tissue to New Technology Group 5 with Caplacizumab, Percutaneous Approach
      • XW013W7 - Introduction Subcutaneous Tissue to New Technology Group 7 with COVID-19 Vaccine Booster, Percutaneous Approach
  • XW01X - External
    • XW01X2
      • XW01X27 - Introduction Subcutaneous Tissue to New Technology Group 7 with Anacaulase-bcdb, External Approach